查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1789636

细胞和基因治疗市场（按治疗类型、应用、最终用户和地区划分）

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
出版日期: | 出版商: Coherent Market Insights | 英文 247 Pages | 商品交期: 2-3个工作天内

价格
简介目录

细胞和基因治疗市场规模预计在 2025 年达到 377 亿美元，预计到 2032 年将达到 1,255 亿美元，2025 年至 2032 年的复合年增长率为 18.5%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 377亿美元
效能数据 从2020年到2024年 预测期 2025年至2032年
预测期：2025-2032年复合年增长率： 18.50% 2032年价值预测 1255亿美元

细胞疗法是透过将新细胞引入患者体内，使其生长、替换或修復受损组织来治疗疾病。细胞疗法可以使用多种细胞类型，包括干细胞、淋巴细胞和树突状细胞。细胞疗法使用来自患者自身的细胞（自体细胞）和来自捐赠者的细胞（同种异体细胞）。许多细胞疗法使用经过基因重编程的成体细胞，这些细胞可以在患者体内发育成多种细胞类型。这项技术有望开发出无限数量的特定人体细胞，以满足治疗需求。

基因治疗旨在修改或导入基因，以治疗、预防或潜在治癒疾病。基因治疗方法包括用功能正常的基因拷贝取代致病突变基因，或将新的、正确的基因拷贝导入体内。

市场动态

细胞和基因疗法在现代医疗保健中发挥着重要作用，因为它提供了可用于基因调控、细胞相互作用、再生能力和重塑的概念和技术。因此，主要市场参与企业正专注于实施各种成长策略，例如产品/平台推出，预计这些策略将在预测期内推动市场成长。例如，2023 年 4 月 4 日，全球医疗保健公司 AmerisourceBergen 宣布推出其细胞和基因疗法 (CGT) 整合中心。该系统可与生物製药公司和供应商的平台集成，促进即时数据交换，并帮助协调疗法开发和患者护理之间的服务。

此外，由 AmerisourceBergen 创新客户关係管理 (CRM) 系统提供支援的跨平台 CGT 整合中心旨在透过为医生和患者服务团队提供整个治疗方法开发和交付流程的可视性，简化医疗流程。透过平台集成，CGT 集成中心将能够：

  • 加快福利调查流程，以便医生输入患者的登记资料后，几乎可以立即获得有关患者保险范围的决定。
  • 为医生和护理经理提供即时治疗进展和交通途径信息，以方便患者安排。
  • 告知案件管理员任何状态变化，例如推迟到达日期，以便他们可以提前与患者和看护者沟通，根据需要修改计划的治疗相关活动和停留时间。

本次调查的主要特点

  • 本报告对全球细胞和基因治疗市场进行了详细分析，提供了预测期（2023-2030 年）的市场规模（十亿美元）和年复合成长率（CAGR），以 2022 年为基准年。
  • 它还强调了各个领域的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球细胞和基因治疗市场的主要企业。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
  • 全球细胞和基因治疗市场报告涉及该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过用于分析全球细胞和基因治疗市场的各种策略矩阵来促进决策。

目录

第一章：调查目标和先决条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章：市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 抑制因素
    • 市场机会
  • 影响分析
  • 合併、收购和合作
  • 监管情景
  • 主要进展
  • PEST分析
  • 技术进步
  • 製造商收益
  • 管道分析

4. 2020-2032 年全球细胞和基因治疗市场（依治疗类型）

  • 细胞疗法
  • 基因治疗

5. 全球细胞和基因治疗市场（按应用），2020 年至 2032 年

  • 皮肤科
  • 肌肉骨骼
  • 肿瘤学
  • 免疫学
  • 心臟病学和神经病学
  • 其他（泌尿问题、感染疾病、眼部疾病、视网膜疾病等）

6. 2020 年至 2032 年全球细胞和基因治疗市场（按最终用户划分）

  • 医院
  • 诊所
  • 其他（研究机构、学术机构等）

7. 2020-2032 年全球细胞和基因治疗市场（按地区）

  • 北美洲
      • 美国
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 欧洲
      • 英国
      • 德国
      • 义大利
      • 法国
      • 西班牙
      • 俄罗斯
      • 其他欧洲国家
  • 亚太地区
      • 中国
      • 印度
      • 日本
      • ASEAN
      • 澳洲
      • 韩国
      • 其他亚太地区
  • 中东
      • GCC
      • 以色列
      • 其他中东地区
  • 非洲
      • 北非
      • 中部非洲
      • 南非

第八章 竞争态势

  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Bluebird Bio, Inc.（Celgene Corporation）
  • Biogen Inc.
  • uniQure NV
  • JCR Pharmaceuticals Co. Ltd.
  • Gene Biotherapeutics
  • Kolon TissueGene, Inc.
  • Horama SA
  • MeiraGTx Limited
  • Gilead Sciences, Inc.
  • Organogenesis, Inc.
  • Orchard Therapeutics Plc.
  • Freeline Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • PTC Therapeutics, Inc.
  • Spark Therapeutics, Inc.
  • Biomarin Pharmaceutical Inc.

第九章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI2475

Cell And Gene Therapy Market is estimated to be valued at USD 37.7 Bn in 2025 and is expected to reach USD 125.5 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 37.7 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 18.50% 2032 Value Projection: USD 125.5 Bn

Cell therapy is the introduction of new cells into a patient's body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient's own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can

  • Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
  • To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
  • Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study

  • This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (USD Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cell and gene therapy market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market.

Market Segmentation

  • Global Cell and Gene Therapy Market, By Therapy Type
    • Cell Therapy
    • Stem Cells
    • T Cells
    • Dendritic Cells
    • NK Cells
    • Gene Therapy
    • Germline Gene Therapy
    • Somatic Gene Therapy
  • Global Cell and Gene Therapy Market, By Application
    • Dermatology
    • Musculoskeletal
    • Oncology
    • Immunology
    • Cardiology & Neurology
    • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
  • Global Cell and Gene Therapy Market, By End user
    • Hospitals
    • Clinics
    • Others (Research Institutes, Academic Institutes, etc.)
  • Global Cell and Gene Therapy Market, By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Bluebird Bio, Inc. (Celgene Corporation)
    • Biogen Inc.
    • uniQure N.V.
    • JCR Pharmaceuticals Co. Ltd.
    • Gene Biotherapeutics
    • Kolon TissueGene, Inc.
    • Horama S.A.
    • MeiraGTx Limited
    • Gilead Sciences, Inc.
    • Organogenesis, Inc.
    • Orchard Therapeutics Plc.
    • Freeline Therapeutics Ltd.
    • Bristol-Myers Squibb Company
    • PTC Therapeutics, Inc.
    • Spark Therapeutics, Inc.
    • Biomarin Pharmaceutical Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapy Type
    • Market Snapshot, By Application
    • Market Snapshot, By End user
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Technological Advancements
  • Manufacturer Revenue
  • Pipeline Analysis

4. Global Cell and Gene Therapy Market, By Therapy Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
      • Germline Gene Therapy
      • Somatic Gene Therapy

5. Global Cell and Gene Therapy Market, By Application, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Dermatology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Musculoskeletal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Cardiology & Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends

6. Global Cell and Gene Therapy Market, By End user, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Research Institutes, Academic Institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cell and Gene Therapy Market, By Region, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Novartis International AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Regeneron Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bluebird Bio, Inc. (Celgene Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • JCR Pharmaceuticals Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gene Biotherapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kolon TissueGene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Horama S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • MeiraGTx Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Organogenesis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Orchard Therapeutics Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Freeline Therapeutics Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PTC Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biomarin Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us